Study Title: Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
 

• Status: Terminated

• Participating Sites:
  • Holden Comprehensive Cancer Center, University of Iowa
  • Penn State Cancer Institute
• Learn more:
  • clinicaltrials.gov: NCT03502681
• Publications and Presentations:
  • European Urology Focus: doi: 10.1016/j.euf.2021.03.005 (Published online, March 17, 2021)